| [Background]With a high incidence rate, non-Hodgkin's lymphoma (NHL) is generally expressed by marrow involvement. Currently, test for NHL bone marrow involvement mainly depends on cell morphology; however the detection rate is relatively low. In recent years, it is reported that flow cytometric immunophenotyping (FCI) is adopted for testing NHL bone marrow involvement. Nevertheless, the accordance ratio between the detection rate of FCI and that of morphology still requires more research. Therefore, this thesis focused on the feasibility of FCI for testing NHL bone marrow involvement.[Purpose]This thesis is intended to discuss the clinical benefits of FCM for testing NHL bone marrow involvement and analyze the relationship between the test results and various clinical features.[Methodology]With CD45-SSC gating and combining three different fluorescence markers, such antigens as CD45, CD10, CD19, CD20, CD22, CD23, CD30, FMC7, Kappa light chains, Lambda light chains, CD3, CD5 and CD7 from 40 marrow samples from NHL patients will be tested the EPICS-XL Flow Cytometry. Meanwhile, they will be tested by marrow cell morphology. The match counting material design method will be adopted for analyzing and comparing the results from the two tests so as to observe their strengths and weaknesses. In addition, the clinical features of the patients will be collected, and the relationship between the test results and clinical features will be analyzed.[Results]1. Among the 40 cases, by FCM test,20 cases (50%) are founded to have marrow involvement, whereas by bone marrow morphology, only 8 cases (20.0%) are founded to have marrow involvement. Tested by match counting material x2, the two tests have significance level (p<0.05), the accordance rate between them is 70.0%(28/40).2. Among the 40 samples from NHL patients tested by FCM,20 patients are found to have marrow involvement and the most expressed monoclonal antibody mareker in B-cell immunofluorescence are: CD19,CD20; this in T-cell is:CD7.3. As for the two cases whose specific type of B-NHL has not been confirmed, the diagnosis can be conducted under the help of FCM.4. Higher Ann Arbor staging may lead to higher detection rate in FCM and marrow cell morthology, however, the former is higher than the latter.5. The influence on the clinical staging: before FCM,5 cases in phaseâ… ,12 cases in phaseâ…¡,10 cases in phaseâ…¢,13 cases in phaseâ…£; after FCM,4 cases in phaseâ… , 7 cases in phaseâ…¡,5 cases in phaseâ…¢,24 cases in phaseâ…£; by x2, P<0.05, the differences have statistics significance.6. With FCM, bone marrow involvement cases are found both in the primary patients and recurring patients, the cases are higher than these found with marrow cell morphology, but they do not demonstrate statistics significance between the primany and recurring patients in the test result of FCM(P>0.05).7. With FCM, the involvement rates of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients are 50.0%,42.9% and 50% respectively.[Conclusion]1. FCM is as effective means to test NHL bone marrow involvement, more sensitive than the bone marrow cell morphology, and it can help the diagnosis, the detection rate of NHL bone marrow in this research is as high as 50%(20/40).2. The immunophenotyping features of NHL patient bone marrow involvement: B-cell:CD19, CD20; T-cell:CD7. 3. FCM heightens the detection rate of bone marrow involvement and help the clinical staging, and it has some directive significance for the clinical staging.4. This research is not complicated and feasible with strong objectivity and high sensitivity, and it is worthy promoting in practice.
|
PDF Full Text Request